Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 407-413 |
| Journal | International journal of oncology |
| Volume | 46 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2015 |
Fingerprint
Keywords
- IR-95620
- METIS-307080
Cite this
}
Circulating tumor cells before and during follow-up after breast cancer surgery. / van Dalum, Guus; Stam, Gert Jan; Tibbe, Arjan G.J.; Franken, Bas; Mastboom, Walter J.B.; Vermes, I.; De Groot, Marco R.; Terstappen, Leonardus Wendelinus Mathias Marie.
In: International journal of oncology, Vol. 46, No. 1, 2015, p. 407-413.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Circulating tumor cells before and during follow-up after breast cancer surgery.
AU - van Dalum, Guus
AU - Stam, Gert Jan
AU - Tibbe, Arjan G.J.
AU - Franken, Bas
AU - Mastboom, Walter J.B.
AU - Vermes, I.
AU - De Groot, Marco R.
AU - Terstappen, Leonardus Wendelinus Mathias Marie
PY - 2015
Y1 - 2015
N2 - The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer
AB - The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC ≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer
KW - IR-95620
KW - METIS-307080
U2 - 10.3892/ijo.2014.2694
DO - 10.3892/ijo.2014.2694
M3 - Article
VL - 46
SP - 407
EP - 413
JO - International journal of oncology
JF - International journal of oncology
SN - 1019-6439
IS - 1
ER -